Your browser doesn't support javascript.
loading
An Acute Infection due to Hepatitis E in the Context of a Patient with Rituximab and Methotrexate Therapy.
Cordero Pérez, Francisco Josué; Martín-Garrido, Eva P; Antona-Herranz, Marta; Bailador-Andrés, Carmen; Conde-Gacho, Pilar; de Diego-Cobos, Clara; Rodriguez-Gomez, Santiago J.
Afiliação
  • Cordero Pérez FJ; Servicio de Medicina Interna, Complejo Asistencial de Zamora, Zamora, Spain.
  • Martín-Garrido EP; Departamento de Medicina, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain.
  • Antona-Herranz M; Servicio de Aparato Digestivo, Complejo Asistencial de Zamora, Zamora, Spain.
  • Bailador-Andrés C; Servicio de Aparato Digestivo, Complejo Asistencial de Zamora, Zamora, Spain.
  • Conde-Gacho P; Servicio de Aparato Digestivo, Complejo Asistencial de Zamora, Zamora, Spain.
  • de Diego-Cobos C; Servicio de Aparato Digestivo, Complejo Asistencial de Zamora, Zamora, Spain.
  • Rodriguez-Gomez SJ; Servicio de Medicina Interna, Complejo Asistencial de Zamora, Zamora, Spain.
Eur J Case Rep Intern Med ; 11(4): 004378, 2024.
Article em En | MEDLINE | ID: mdl-38584892
ABSTRACT

Background:

This report presents the influence of immunosuppression by new rheumatological therapies on hepatitis E virus infection in a 54-year-old male patient with an anti-synthetase syndrome and treatment with methotrexate and rituximab. Case description The patient arrived at the Emergency Department with epigastric pain, vomiting and dark urine. Initial examination revealed signs of inflammation and hepatic dysfunction. Subsequent laboratory tests and imaging confirmed acute hepatitis E infection in the context of recent initiation of rituximab therapy. Despite initial suspicion of pancreatitis, subsequent investigations ruled out pancreatic involvement. Treatment with ribavirin, along with supportive measures, led to significant clinical improvement with resolution of jaundice, ascites, and oedema.

Conclusions:

This case underscores the importance of considering hepatitis E in patients with autoimmune conditions, especially when initiating immunosuppressive therapies, a situation that is not well described in scientific literature and is increasingly common, necessitating proper recognition. LEARNING POINTS Suspect hepatitis E virus infection in the presence of persistent liver failure of unknown cause.Recognise immunosuppression as a cause of increased risk of hepatitis E infection.Take into account the repercussions of immunosuppressive therapy such as rituximab regarding hepatitis E infections in immunocompromised patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Eur J Case Rep Intern Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Eur J Case Rep Intern Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha